U.S. Paper and Forestry Products Stock News

NasdaqGS:XMTR
NasdaqGS:XMTRTrade Distributors

Is Xometry (XMTR) Undervalued After Earnings Growth And Higher 2026 Guidance?

Xometry (XMTR) is back in focus after its 4 August 2026 earnings report, which showed higher quarterly and year to date sales, narrower net losses and an updated outlook for the rest of 2026. See our latest analysis for Xometry. Despite a 1 day share price return of down 5.7% to US$87.09 after the 4 August earnings release, Xometry’s year to date share price return of 38.8% and 1 year total shareholder return of 102.2% suggest momentum has been building over a longer window. The 3 year total...
NYSE:ICE
NYSE:ICECapital Markets

Is Intercontinental Exchange (ICE) Fairly Priced Or Too Expensive Now?

Intercontinental Exchange stock has delivered a 35.4% gain over the past three years, yet the current checks send a mixed message as the Excess Returns intrinsic value estimate points to a roughly fair price while earnings based multiples lean expensive. Over the last three years, Intercontinental Exchange shares are up 35.4%, which puts recent weakness into context after a tougher past year. Planned expansion in fixed income trading and data, including the agreed MarketAxess acquisition and...
NYSE:IFF
NYSE:IFFChemicals

Why International Flavors & Fragrances (IFF) Is Up 6.4% After New $2.5 Billion Buyback And Guidance

International Flavors & Fragrances Inc. recently reported second-quarter 2026 results showing slightly higher sales of US$1,954 million but a sharp drop in net income to US$50 million, alongside updated full-year guidance reflecting discontinued operations. At the same time, the company unveiled a new US$2.50 billion share repurchase program and affirmed its regular quarterly dividend, underscoring management’s capital return priorities during its portfolio reshaping. We’ll now examine how...
NasdaqGS:PLUS
NasdaqGS:PLUSElectronic

Is ePlus (PLUS) Undervalued Following Strong Bookings And Reiterated 2027 Outlook?

ePlus (PLUS) drew investor attention after reporting modest revenue growth for the fiscal first quarter of 2027, highlighting higher bookings and open orders tied to demand for AI infrastructure, security, cloud, and managed services. See our latest analysis for ePlus. At a share price of $90.35, ePlus has seen short term share price momentum cool after the earnings release, with a 1 day share price return that declined 4.45%. However, the 1 month share price return of 7.78% and 1 year total...
NasdaqGM:ETON
NasdaqGM:ETONPharmaceuticals

Eton Pharmaceuticals (ETON) Stock Could Be Pricey On A Very Large Three Year Run

Eton Pharmaceuticals stock has delivered very strong long term gains for shareholders over the last three years, yet the current checks suggest the shares now lean expensive rather than obviously cheap. Eton Pharmaceuticals has returned about 16.8x over the last three years, which puts extra focus on whether the recent share price now runs ahead of business fundamentals. Expectations that Eton Pharmaceuticals can keep building its product revenues and cash flows may support the current...